ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Organigram Global (OGI)
Organigram Global stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ
$0.94▲ +0.02%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Organigram Global in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Organigram Global
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Organigram Global a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.86 and $1.02; in 9 out of 10, between $0.75 and $1.17. Estimated annual volatility is 38%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $134M
- P/E ratio
- 2.2
- 52-week high
- $2.24
- 52-week low
- $0.85
- Revenue (12 months)
- $217M
- Revenue growth (YoY)
- +123.4%
- Gross margin
- 34.8%
- Operating margin
- -5.9%
- Net margin
- -9.6%
- Return on equity
- 17.6%
- Free cash flow (12 months)
- $-0.9M
- Beta
- 1.91
What this means
ATLAS does not publish a fair value for OGI right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks OGI has traded between $0.85 and $2.24. Today it is 58.1% below that high and 11% above its low.
On the business: revenue grew 123.4% year over year; net margin is 9.6%; it trades at 2.2 times earnings.
Its beta is 1.91: it tends to move more than the market, both up and down.
About the company
Organigram Global Inc. is a Canadian cannabis company focused on the production and sale of cannabis and cannabis-derived products for medical and adult-use markets.
Want to see everything about Organigram Global?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Organigram Global do?
Organigram Global Inc. is a Canadian cannabis company focused on the production and sale of cannabis and cannabis-derived products for medical and adult-use markets.
What is the chance OGI goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, OGI ends the month between $0.86 and $1.02.
How big is Organigram Global and what is its P/E ratio?
Organigram Global's market capitalization is $134M. Its price-to-earnings (P/E) ratio is 2.2: you pay $2.2 for each $1 of yearly earnings.
How volatile is OGI?
ATLAS estimates annual volatility at 38%. In a typical month, half of the outcomes end between $0.86 and $1.02.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer